Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

Quiz on clinical trials of head & neck day 1

quiz on clinical trials of head and neck cancer

  • Loggen Sie sich ein, um Kommentare anzuzeigen.

Quiz on clinical trials of head & neck day 1

  1. 1. Quiz time KBC- KAUN BANEGA CHAMPION
  2. 2. Theory round
  3. 3. Q1- Cooper trial 1- Cooper Trial is ECOG / RTOG ________ . 2- comment on overall survival __________ between two arms.?
  4. 4. 1- Cooper Trial is ECOG / RTOG __9501______ . 2- comment on overall survival- __ no significant difference ___ between two arms.
  5. 5. Q2- Cooper trial- update 2012 1- Two arms _______ , ____________. 2- patient with microscopically involved resection margins and ECS of disease showed improved _____________ and ___________.
  6. 6. 1-No significant differences in outcome was observed in the analysis of all eligible patients randomized in two __ Postop. ,__ CTRT vs RT____. 2- patient with microscopically involved resection margins nad ECS of disease showed improved ___LRC____ and _____DFS______.
  7. 7. Q-3 Bonner trial • Fill in the blank- 1- progression free survival better in_______arm. 2- With the exception of_________and_______ , the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups.
  8. 8. • Fill in the blank- 1- progression free survival better in___RT + cituximab_____arm. 2- With the exception of ___acneiform rash___ and __infusion reactions___ , the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups.
  9. 9. Q4- Bernier trial 1- Compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage ___________ of head and neck cancer. 2- Bernier trial is EORTC _______ .
  10. 10. • 1- Compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for __stage III or IV__head and neck cancer. • 2- Bernier trial is EORTC __22931__ .
  11. 11. Q5- EORTC 24891-Lefebvre et.al. 1- It is Randomized Trial on ___________ Comparing Sequential vs Alternating Chemotherapy and Radiotherapy . 2- Induction chemotherapy consisted of______________ .
  12. 12. 1- It is Randomized Trial on ___ laryngial preservation ___ Comparing Sequential vs Alternating Chemotherapy and Radiotherapy . 2- Induction chemotherapy consisted of __cisplatin and 5FU_____ .
  13. 13. Q6- EORTC 24891-Lefebvre et.al UPDATE 1- comparing a larynx-preservation approach to immediate surgery in __________ and lateral epilarynx squamous cell carcinoma. 2- The 10-year OS rate was 13.8% in the surgery arm and 13.1% in the chemotherapy arm. The 10-year ___________rates were 8.5% and 10.8%, respectively. In the chemotherapy arm, the 10-year SFL rate was 8.7%.
  14. 14. 1- comparing a larynx-preservation approach to immediate surgery in __Hypopharynx_____ and lateral epilarynx squamous cell carcinoma. 2- The 10-year OS rate was 13.8% in the surgery arm and 13.1% in the chemotherapy arm. The 10- year ___PFS ____rates were 8.5% and 10.8%, respectively. In the chemotherapy arm, the 10- year SFL rate was 8.7%.
  15. 15. Q7- GORTEC 99-02 1- Randomly allocated patients in 3 arm- - conventional chemoradiotherapy - ? - very accelerated radiotherapy alone.
  16. 16. 1- Randomly allocated patients IN 3 arm- - conventional chemoradiotherapy. - Accelerated chemoradiotherapy. - very accelerated radiotherapy alone.
  17. 17. Q8- GORTEC 99-02 • Enrolled patients with stage _________________(non-metastatic) HNSCC, suggested that acceleration of radiotherapy is probably ?not beneficial or beneficial? in concomitant chemoradiotherapy schedules.
  18. 18. • Enrolled patients with locally advanced,______ stage III and IV___ (non- metastatic) HNSCC, suggested that acceleration of radiotherapy is probably____ not beneficial _____in concomitant chemoradiotherapy schedules.
  19. 19. Q9- Al-Sarraf- Intergroup Study 0099 1- compared chemoradiotherapy versus ______________ in patients with ______________cancers and conclude results in term of PFS and___________ which were better in ____________ arm. 2- publised in ___________ .
  20. 20. 1- compared chemoradiotherapy versus ___radiotherapy alone __in patients with ___nasopharyngeal___ cancers and conclude results in term of PFS and___OS___ which were better in ____ chemoradiotherapy___ arm. 2- publised in ___1998___ .
  21. 21. Q10- IMRT for nasopharynx (Suzanne et.al.) 1- IMRT has significantly impoved in radiation dose distribution over 3DCRT and Rate of severe ___________ and xerostomia are low as a normal tissue protections for Ca Nasopharynx .
  22. 22. • 1- IMRT has significantly impoved in radiation dose distribution over 3DCRT and Rate of severe __ototoxicity__ and xerostomia are low as a normal tissue protections for Ca Nasopharynx .
  23. 23. Q11- The MARCH-HPV project 1- Published in which publication ? 2- Compared to p16- negative, p16- positive patient had significantly better _____ and OS.
  24. 24. 1- Published in “ GREEN journal” publication. 2- compared to p16- negative, p16- positive patient had significantly better __PFS and OS___ .
  25. 25. Q12- The MARCH-HPV project • For p16 positive patients- 1- no predictive impact on response to ______ . 2. Strong prognostic impact of outcome especialy in ________ .
  26. 26. • For p16 positive patients- 1- no predictive impact on response to __AFRT____ . 2. Strong prognostic impact of outcome especialy in __Never Smoking Patient ____ .
  27. 27. Score please …..
  28. 28. Image Round
  29. 29. Q13 – Bonner trial update 1-blue line and orange line denote for-
  30. 30. • Blue line – Prominent rash (grade 2–4) • Orange line -Mild rash (none/grade 1)
  31. 31. 1- ? ? Q14- Cooper trial- update 2012
  32. 32. 1- RT RT+CT Cooper trial- update 2012
  33. 33. Q15- Bernier trial ? ?
  34. 34. Bernier trial
  35. 35. Q16- EORTC 24891-Lefebvre et.al. ? ?
  36. 36. EORTC 24891-Lefebvre et.al. OS or PFS
  37. 37. Score Please …….
  38. 38. Recovary/Boost buzzer round
  39. 39. 1 ……
  40. 40. 2…….
  41. 41. 3……
  42. 42. Q17- Human papillomavirus/p16 positive head and neck cancer in India • The low prevalence of p16 positivity (20%) and dual HPV and p16 positivity (38.8%) in the studied Indian cohort indicates the low utility of p16 as a surrogate for HPV in the background of _________________ .
  43. 43. • The low prevalence of p16 positivity (20%) and dual HPV and p16 positivity (38.8%) in the studied Indian cohort indicates the low utility of p16 as a surrogate for HPV in the background of ___high tobacco burden___.
  44. 44. Mismatch round
  45. 45. Q-18 Trial Year of publication Cooper 2004 Bonner 2006 Bernier 2003 Al-Sarraf 1998
  46. 46. Trial Year of publication Cooper 2004 Bonner 2006 Bernier 2004 Al-sarraf 1998
  47. 47. Q -19 Trial Study group Al-sarraf Intergroup Study 0099 bernier EORTC 22331 Cooper RTOG 9501 Lefebvre EORTC trial 24891
  48. 48. Trial Study group Al-sarraf Intergroup Study 0099 Bernier EORTC 22931 Cooper RTOG 9501 Lefebvre EORTC trial 24891
  49. 49. Q-20 Trial Subset of patients Lefebvre Patients with unresectable advanced squamous cell carcinoma of the larynx bonner Stage III AND Stage IV patients head and neck all site Bernier Postoperative head and neck of all site
  50. 50. Trial Subset of patients Lefebvre Patients with resectable advanced squamous cell carcinoma of the larynx OR hypopharynx Bonner Stage III AND Stage IV patients head and neck all site except nasopharynx Bernier Postoperative head and neck of all site except nasopharynx
  51. 51. Q-21 Trial Primary End point GORTEC 99-02 PFS Cooper DFS and OS Bonner PFS
  52. 52. Trial Primary End point GORTEC 99-02 PFS Cooper DFS and OS Bonner LRC
  53. 53. Score please……
  54. 54. The Final Buzzer ….. Do or die …..
  55. 55. Q22-The MARCH-HPV project 1. How many redomid trials were included? 2. name the trials?
  56. 56. 1- 4 trials 2- RTOG 9003 DAHANCA A6&7 RTOG 0129 ARTSCAN
  57. 57. • End of part 1 Thank you!! KBC- KAUN BANEGA CHAMPION

×